Lumiradx receives who emergency use listing for sars-cov-2 ag test

London , may 20, 2022 /prnewswire/ -- lumiradx limited (nasdaq: lmdx), a next-generation point of care diagnostics company, announced today that its rapid covid-19 antigen assay, lumiradx sars-cov-2 ag test has successfully received the emergency use listing (eul) by the world health organization (who) in their latest response effort to combat covid-19. the lumiradx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct and qualitative detection of nucleocapsid protein antigen in nasal swab specimens collected from the patient.
LMDX Ratings Summary
LMDX Quant Ranking